LON:PRM Proteome Sciences (PRM) Share Price, News & Analysis GBX 3.28 +0.24 (+7.89%) As of 08/1/2025 05:36 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About Proteome Sciences Stock (LON:PRM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Proteome Sciences alerts:Sign Up Key Stats Today's Range 2.73▼ 3.2850-Day Range 2.61▼ 3.7852-Week Range 2.22▼ 5.40Volume87,000 shsAverage Volume204,325 shsMarket Capitalization£9.68 millionP/E RatioN/ADividend Yield6.17%Price TargetN/AConsensus RatingN/A Company Overview Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also provides top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom. Read More Receive PRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Proteome Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PRM Stock News HeadlinesProteome Sciences shares rise as chair hails rebound in businessMay 16, 2025 | lse.co.ukProteome Sciences Full Year 2024 Earnings: UK£0.011 loss per share (vs UK£0.008 loss in FY 2023)April 12, 2025 | finance.yahoo.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 2 at 2:00 AM | Porter & Company (Ad)Proteome Sciences Secures £1 Million Loan to Boost Capacity Amid Market GrowthDecember 23, 2024 | tipranks.comProteomics and AI unite for a new era in medicine and health careDecember 12, 2024 | msn.comNanoparticle approach enhances detection of low-abundance proteins in blood plasmaNovember 9, 2024 | msn.comProteome Sciences plc (PRM.L)November 6, 2024 | finance.yahoo.comBruker Announces One-Hundred Dollar, Deep, High-Accuracy Plasma Proteome; Advances Glycoproteomics and MetaproteomicsOctober 21, 2024 | tmcnet.comSee More Headlines PRM Stock Analysis - Frequently Asked Questions How have PRM shares performed this year? Proteome Sciences' stock was trading at GBX 3.40 at the beginning of the year. Since then, PRM shares have decreased by 3.5% and is now trading at GBX 3.28. How were Proteome Sciences' earnings last quarter? Proteome Sciences plc (LON:PRM) issued its quarterly earnings results on Thursday, April, 10th. The company reported ($1.15) earnings per share for the quarter. Proteome Sciences had a negative net margin of 0.04% and a negative trailing twelve-month return on equity of 0.01%. How do I buy shares of Proteome Sciences? Shares of PRM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Proteome Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Proteome Sciences investors own include Lloyds Banking Group (LLOY), Petrofac (PFC), ValiRx (VAL), boohoo group (BOO), Intel (INTC), Mondi (MNDI) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings4/10/2025Today8/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Diagnostics & Research Sub-IndustryChemicals Current SymbolLON:PRM CIKN/A Webwww.proteomics.com Phone+44-20-70432116FaxN/AEmployees240Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£4.08 million Net Margins-0.04% Pretax MarginN/A Return on Equity-0.01% Return on Assets-19.25% Debt Debt-to-Equity Ratio-258.66 Current Ratio0.20 Quick Ratio0.37 Sales & Book Value Annual Sales£10.88 billion Price / Sales0.00 Cash FlowGBX 0.88 per share Price / Cash Flow3.73 Book ValueGBX (1.78) per share Price / Book-1.84Miscellaneous Outstanding Shares295,167,274Free FloatN/AMarket Cap£9.68 million OptionableNot Optionable Beta0.07 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (LON:PRM) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteome Sciences plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteome Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.